article thumbnail

STAT+: FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system

STAT

The latest report accuses the PBMs – CVS Caremark, OptumRx and Express Scripts, all of which are owned by large health insurers – of boosting prices of specialty generic drugs that are sold through their own pharmacies. Specifically, the companies were able to generate more than $7.3

Insurance 142
article thumbnail

Insurance stopped covering my GLP-1: What to do next

The Checkup by Singlecare

Although health insurance companies tend to cover GLP-1 agonists as a treatment for Type 2 diabetes, coverage for weight loss is less common. That said, insurance formularies can change for a variety of reasons, and it can be frustrating to find that your GLP-1 medication is no longer covered. By 2022, that number had jumped to 179.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Insulin statistics 2025

The Checkup by Singlecare

Diabetes statistics worldwide As of 2022, 830 million people worldwide were living with diabetes. Global diabetes prevalence quadrupled from 1990 to 2022. In 2022, more than 50% of people with diabetes were not taking medication for their condition. ADA , 2022 ) About 5.7% How many Americans use insurance for insulin?

article thumbnail

STAT+: Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more

STAT

The latest report accuses the PBMs — CVS Caremark, Optum Rx, and Express Scripts, all of which are owned by large health insurers — of boosting prices of specialty generic drugs that are sold through their own pharmacies. Specifically, the companies were able to generate more than $7.3

Insurance 101
article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

FDA approves first generic once-daily GLP-1 medication

The Checkup by Singlecare

The popularity of these medications created a surge in demand, which led to shortages of some GLP-1 receptor agonists that began in 2022. The cost of the name-brand version varies , based on pharmacy and health insurance coverage. We are very pleased to launch liraglutide injection immediately upon receiving U.S.

FDA 105
article thumbnail

STAT+: Congress nears deal to rein in PBMs after years of debate

STAT

Passage of laws to address pharmacy middlemen has been the top priority of the pharmaceutical industry, particularly after they suffered a stinging defeat when Democrats passed their drug pricing law in 2022. The pharma industry spent millions on advertising to promote PBM legislation, and it appears it will get most of what it wanted. 

Packaging 135